Inventor
PENGLIE ZHANG
Inventor
US
Overview
Patents· 42 as inventor
Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.
A61Kprimary
A61KPreparations for medical, dental or toiletry purposes28%
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations28%
C07DHeterocyclic compounds24%
Y02ATechnologies for adaptation to climate change5%
C07CAcyclic or carbocyclic compounds4%
C07FAcyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium4%
C07BGeneral methods of organic chemistry3%
C07KPeptides3%
G01NInvestigating or analysing materials by determining their chemical or physical properties1%
PatentTitleYear
12,533,354Triaryl compounds for treatment of PD-L1 diseases202612,497,383Heteroaryl-biphenyl amides for the treatment of PD-L1 diseases202512,448,373Azetidinyl-acetamides as CXCR7 inhibitors202512,371,433Heteroaryl-biphenyl amines for the treatment of PD-L1 diseases202512,268,675Diaryl substituted 6,5-fused ring compounds as C5aR inhibitors202512,139,4752-oxindole compounds202412,054,484Substituted tetrahydropyrans as CCR2 modulators202412,018,016Aryl sulfonyl (hydroxy) piperidines as CCR6 inhibitors202412,012,403Aryl sulfonyl compounds as CCR6 inhibitors202412,011,439Combination therapy using C--C chemokine receptor 4 (CCR4) antagonists and one or more immune checkpoint inhibitors202411,945,805Inhibitors of CXCR2202411,883,391Compositions and methods for treating inflammatory bowel disease using CCR9 inhibitor and anti-IL-23 blocking antibodies202411,872,217Indanes as PD-L1 inhibitors202411,866,429Heteroaryl-biphenyl amines for the treatment of PD-L1 diseases202411,845,729Processes and intermediates in the preparation of C5aR antagonists202311,834,452CXCR7 antagonists202311,820,759Modulators of chemokine receptors202311,807,609Deuterated compounds as immunomodulators202311,793,771Immunomodulator compounds202311,773,0916-5 fused rings as C5a inhibitors202311,759,458Indane-amines as PD-L1 antagonists202311,759,454Diazole lactams202311,744,822Reducing tumor burden by administering CCR1 antagonists in combination with PD-1 inhibitors or PD-L1 inhibitors202311,713,307Heteroaryl-biphenyl amides for the treatment of PD-L1 diseases202311,708,326Immunomodulator compounds202311,691,985Macrocyclic immunomodulators202311,684,606Methods of treating generalized pustular psoriasis with an antagonist of CCR6 or CXCR2202311,608,336Prodrugs of fused-bicyclic C5aR antagonists202311,603,356Amorphous form of a complement component C5a receptor202311,485,708Compounds for treatment of PD-L1 diseases202211,485,737Diaryl substituted 5,5-fused ring compounds as C5aR inhibitors202211,479,5535-5 fused rings as C5a inhibitors202211,478,460Diaryl substituted 6,5-fused ring compounds as C5aR inhibitors202211,446,289Combination therapy using C-C chemokine receptor 4 (CCR4) antagonists and one or more immune checkpoint inhibitors202211,434,2302-oxindole compounds202211,427,541Salt forms of a complement component C5A receptor202211,426,364Immunomodulator compounds202211,384,0796-5 fused rings as C5a inhibitors202211,266,643Triaryl compounds for treatment of PD-L1 diseases202211,254,695Soluble C5aR antagonists202211,207,294Methods of treating generalized pustular psoriasis with an antagonist of CCR6 or CXCR2202111,135,210Indane-amines as PD-L1 antagonists2021Career & activity timeline
Assembled from patent assignee/location history and declaration credentials.
2021–2026Patents assigned to CHEMOCENTRYX INC (42)· patent assignee history
2021–2026Based in US· patent location history
2024–2025Patents assigned to AMGEN INC (3)· patent assignee history
Inventor activity
Assignee and location history derived from the patent record.
Assignees
| Assignee | Patents | Span |
|---|---|---|
| CHEMOCENTRYX INC | 42 | 2021–2026 |
| AMGEN INC | 3 | 2024–2025 |
Locations
| Location | Patents | Span |
|---|---|---|
| US | 42 | 2021–2026 |